Erratum: Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles (ACS Nano (2015) 9:9 (8976−8996) DOI: 10.1021/acsnano.5b02913);Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles

ACS Nano

Volumn 9, Issue 9, 2015, Pages 8976-8996

  Au, Kin Man ^a,b   Min, Yuanzeng ^a,b   Tian, Xi ^a,b   Zhang, Longzhen ^c   Perello, Virginia ^a,b   Caster, Joseph M ^a,b   Wang, Andrew Z ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

cancer; combination chemotherapy; concurrent chemoradiotherapy; diblock copolymer NPs; dual drug encapsulation; dynamic rewiring of cell apoptotic pathways

Indexed keywords

BLOCK COPOLYMERS; CANCER CELLS; CELL DEATH; CELL SIGNALING; CHEMORADIOTHERAPY; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; DRUG PRODUCTS; EFFICIENCY; ENCAPSULATION; TARGETED DRUG DELIVERY; TOXICITY;

APOPTOTIC PATHWAYS; CANCER; COMBINATION CHEMOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; DIBLOCK COPOLYMER NANOPARTICLE; DIBLOCK-COPOLYMER; DRUG ENCAPSULATION; DUAL DRUG ENCAPSULATION; DYNAMIC REWIRING OF CELL APOPTOTIC PATHWAY; THERAPEUTIC EFFICACY;

NANOPARTICLES;

ANDROSTANE DERIVATIVE; DELAYED RELEASE FORMULATION; DOCETAXEL; NANOPARTICLE; TAXOID; WORTMANNIN;

ANIMAL; APOPTOSIS; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANDROSTADIENES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MICE; NANOPARTICLES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942155144     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.4c05756     Document Type: Erratum

References (52)

1. Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer Statistics, 2015 Ca-Cancer J. Clin. 2015, 65, 5-29 10.3322/caac.21254
2. Ross, G. M. Induction of Cell Death by Radiotherapy Endocr.-Relat. Cancer 1999, 6, 41-44 10.1677/erc.0.0060041
3. Baskar, R.; Lee, K. A.; Yeo, R.; Yeoh, K. W. Cancer and Radiation Therapy: Current Advances and Future Directions Int. J. Med. Sci. 2012, 9, 193-199 10.7150/ijms.3635
4. Seiwert, T. Y.; Salama, J. K.; Vokes, E. E. The Concurrent Chemoradiation Paradigm - General Principles Nat. Clin. Pract. Oncol. 2007, 4, 86-100 10.1038/ncponc0714
5. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U. et al. Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma N. Engl. J. Med. 2005, 352, 987-996 10.1056/NEJMoa043330
6. Willett, C. G.; Czito, B. G. Chemoradiotherapy in Gastrointestinal Malignancies Clin Oncol (R Coll Radiol) 2009, 21, 543-556 10.1016/j.clon.2009.05.004
7. Eifel, P. J. Chemoradiotherapy in the Treatment of Cervical Cancer Semin Radiat Oncol 2006, 16, 177-185 10.1016/j.semradonc.2006.02.007
8. Curran, W. J., Jr.; Paulus, R.; Langer, C. J.; Komaki, R.; Lee, J. S.; Hauser, S.; Movsas, B.; Wasserman, T.; Rosenthal, S. A.; Gore, E. et al. Sequential Vs. Concurrent Chemoradiation for Stage Iii Non-Small Cell Lung Cancer: Randomized Phase Iii Trial Rtog 9410 J. Natl. Cancer Inst 2011, 103, 1452-1460 10.1093/jnci/djr325
9. Forastiere, A. A.; Goepfert, H.; Maor, M.; Pajak, T. F.; Weber, R.; Morrison, W.; Glisson, B.; Trotti, A.; Ridge, J. A.; Chao, C. et al. Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer N. Engl. J. Med. 2003, 349, 2091-2098 10.1056/NEJMoa031317
10. Ajani, J. A.; Winter, K. A.; Gunderson, L. L.; Pedersen, J.; Benson, A. B., 3rd; Thomas, C. R., Jr.; Mayer, R. J.; Haddock, M. G.; Rich, T. A.; Willett, C. Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial JAMA 2008, 299, 1914-1921 10.1001/jama.299.16.1914
11. Habr-Gama, A.; Perez, R. O.; Nadalin, W.; Sabbaga, J.; Ribeiro, U., Jr.; Silva e Sousa, A. H., Jr.; Campos, F. G.; Kiss, D. R.; Gama-Rodrigues, J. Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-Term Results Ann. Surg. 2004, 240, 711-717 discussion 717-718. 10.1097/01.sla.0000141194.27992.32
12. Maas, M.; Beets-Tan, R. G.; Lambregts, D. M.; Lammering, G.; Nelemans, P. J.; Engelen, S. M.; van Dam, R. M.; Jansen, R. L.; Sosef, M.; Leijtens, J. W. et al. Wait-and-See Policy for Clinical Complete Responders after Chemoradiation for Rectal Cancer J. Clin. Oncol. 2011, 29, 4633-4640 10.1200/JCO.2011.37.7176
13. James, N. D.; Hussain, S. A.; Hall, E.; Jenkins, P.; Tremlett, J.; Rawlings, C.; Crundwell, M.; Sizer, B.; Sreenivasan, T.; Hendron, C. et al. Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer N. Engl. J. Med. 2012, 366, 1477-1488 10.1056/NEJMoa1106106
14. Cooper, J. S.; Pajak, T. F.; Forastiere, A. A.; Jacobs, J.; Campbell, B. H.; Saxman, S. B.; Kish, J. A.; Kim, H. E.; Cmelak, A. J.; Rotman, M. et al. Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck N. Engl. J. Med. 2004, 350, 1937-1944 10.1056/NEJMoa032646
15. Shenoy, M. A.; Singh, B. B. Chemical Radiosensitizers in Cancer Therapy Cancer Invest. 1992, 10, 533-551 10.3109/07357909209024816
16. Lee, M. J.; Ye, A. S.; Gardino, A. K.; Heijink, A. M.; Sorger, P. K.; MacBeath, G.; Yaffe, M. B. Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks Cell 2012, 149, 780-794 10.1016/j.cell.2012.03.031
17. Al-Lazikani, B.; Banerji, U.; Workman, P. Combinatorial Drug Therapy for Cancer in the Post-Genomic Era Nat. Biotechnol. 2012, 30, 679-692 10.1038/nbt.2284
18. Morton, S. W.; Lee, M. J.; Deng, Z. J.; Dreaden, E. C.; Siouve, E.; Shopsowitz, K. E.; Shah, N. J.; Yaffe, M. B.; Hammond, P. T. A Nanoparticle-Based Combination Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of Signaling Pathways Sci. Signaling 2014, 7, ra44 10.1126/scisignal.2005261
19. Mason, K. A.; Hunter, N. R.; Milas, M.; Abbruzzese, J. L.; Milas, L. Docetaxel Enhances Tumor Radioresponse in Vivo Clin. Cancer Res. 1997, 3, 2431-2438
20. Mason, K. A.; Kishi, K.; Hunter, N.; Buchmiller, L.; Akimoto, T.; Komaki, R.; Milas, L. Effect of Docetaxel on the Therapeutic Ratio of Fractionated Radiotherapy in Vivo Clin. Cancer Res. 1999, 5, 4191-4198
21. Rabi, T.; Bishayee, A. D-Limonene Sensitizes Docetaxel-Induced Cytotoxicity in Human Prostate Cancer Cells: Generation of Reactive Oxygen Species and Induction of Apoptosis J. Carcinog. 2009, 8, 9 10.4103/1477-3163.51368
22. Wipf, P.; Halter, R. J. Chemistry and Biology of Wortmannin Org. Biomol. Chem. 2005, 3, 2053-2061 10.1039/b504418a
23. Price, B. D.; Youmell, M. B. The Phosphatidylinositol 3-Kinase Inhibitor Wortmannin Sensitizes Murine Fibroblasts and Human Tumor Cells to Radiation and Blocks Induction of P53 Following DNA Damage Cancer Res. 1996, 56, 246-250
24. Rosenzweig, K. E.; Youmell, M. B.; Palayoor, S. T.; Price, B. D. Radiosensitization of Human Tumor Cells by the Phosphatidylinositol3-Kinase Inhibitors Wortmannin and Ly294002 Correlates with Inhibition of DNA-Dependent Protein Kinase and Prolonged G2-M Delay Clin. Cancer Res. 1997, 3, 1149-1156
25. Sarkaria, J. N.; Tibbetts, R. S.; Busby, E. C.; Kennedy, A. P.; Hill, D. E.; Abraham, R. T. Inhibition of Phosphoinositide 3-Kinase Related Kinases by the Radiosensitizing Agent Wortmannin Cancer Res. 1998, 58, 4375-4382
26. Zhang, F.; Zhang, T.; Qu, Y.; Jiang, T.; Cao, Y. X.; Li, C.; Fan, L.; Mei, Q. B. Replication-Dependent -H2ax Formation Is Involved in Docetaxel-Induced Apoptosis in Nsclc A549 Cells Oncol. Rep. 2010, 24, 1297-1305 10.3892/or00000986
27. Caster, J. M.; Sethi, M.; Kowalczyk, S.; Wang, E.; Tian, X.; Nabeel Hyder, S.; Wagner, K. T.; Zhang, Y. A.; Kapadia, C.; Man, A. K. et al. Nanoparticle Delivery of Chemosensitizers Improve Chemotherapy Efficacy without Incurring Additional Toxicity Nanoscale 2015, 7, 2805-2811 10.1039/C4NR07102F
28. Karve, S.; Werner, M. E.; Sukumar, R.; Cummings, N. D.; Copp, J. A.; Wang, E. C.; Li, C.; Sethi, M.; Chen, R. C.; Pacold, M. E. et al. Revival of the Abandoned Therapeutic Wortmannin by Nanoparticle Drug Delivery Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 8230-8235 10.1073/pnas.1120508109
29. Sethi, M.; Sukumar, R.; Karve, S.; Werner, M. E.; Wang, E. C.; Moore, D. T.; Kowalczyk, S. R.; Zhang, L.; Wang, A. Z. Effect of Drug Release Kinetics on Nanoparticle Therapeutic Efficacy and Toxicity Nanoscale 2014, 6, 2321-2327 10.1039/c3nr05961h
30. Govender, T.; Stolnik, S.; Garnett, M. C.; Illum, L.; Davis, S. S. PLGA Nanoparticles Prepared by Nanoprecipitation: Drug Loading and Release Studies of a Water Soluble Drug J. Controlled Release 1999, 57, 171-185 10.1016/S0168-3659(98)00116-3
31. Tetko, I. V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V. A.; Radchenko, E. V.; Zefirov, N. S.; Makarenko, A. S. et al. Virtual Computational Chemistry Laboratory - Design and Description J. Comput.-Aided Mol. Des. 2005, 19, 453-463 10.1007/s10822-005-8694-y
32. Barzegar-Jalali, M.; Adibkia, K.; Valizadeh, H.; Shadbad, M. R.; Nokhodchi, A.; Omidi, Y.; Mohammadi, G.; Nezhadi, S. H.; Hasan, M. Kinetic Analysis of Drug Release from Nanoparticles J. Pharm. Pharm. Sci. 2008, 11, 167-177
33. Chithrani, B. D.; Chan, W. C. Elucidating the Mechanism of Cellular Uptake and Removal of Protein-Coated Gold Nanoparticles of Different Sizes and Shapes Nano Lett. 2007, 7, 1542-1550 10.1021/nl070363y
34. Win, K. Y.; Feng, S. S. Effects of Particle Size and Surface Coating on Cellular Uptake of Polymeric Nanoparticles for Oral Delivery of Anticancer Drugs Biomaterials 2005, 26, 2713-2722 10.1016/j.biomaterials.2004.07.050
35. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of Functionalized Plga-Peg Nanoparticles for in Vivo Targeted Drug Delivery Biomaterials 2007, 28, 869-876 10.1016/j.biomaterials.2006.09.047
36. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted Delivery of Cisplatin to Prostate Cancer Cells by Aptamer Functionalized Pt(Iv) Prodrug-Plga-Peg Nanoparticles Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 17356-17361 10.1073/pnas.0809154105
37. Gu, F.; Zhang, L.; Teply, B. A.; Mann, N.; Wang, A.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Precise Engineering of Targeted Nanoparticles by Using Self-Assembled Biointegrated Block Copolymers Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 2586-2591 10.1073/pnas.0711714105
38. Franken, N. A.; Rodermond, H. M.; Stap, J.; Haveman, J.; van Bree, C. Clonogenic Assay of Cells in Vitro Nat. Protoc 2006, 1, 2315-2319 10.1038/nprot.2006.339
39. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles Mol. Pharmaceutics 2008, 5, 505-515 10.1021/mp800051m
40. Chu, K. S.; Hasan, W.; Rawal, S.; Walsh, M. D.; Enlow, E. M.; Luft, J. C.; Bridges, A. S.; Kuijer, J. L.; Napier, M. E.; Zamboni, W. C. et al. Plasma, Tumor and Tissue Pharmacokinetics of Docetaxel Delivered Via Nanoparticles of Different Sizes and Shapes in Mice Bearing Skov-3 Human Ovarian Carcinoma Xenograft Nanomedicine 2013, 9, 686-693 10.1016/j.nano.2012.11.008
41. Klibanov, A. L.; Maruyama, K.; Torchilin, V. P.; Huang, L. Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time of Liposomes FEBS Lett. 1990, 268, 235-237 10.1016/0014-5793(90)81016-H
42. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C. Cancer Nanotechnology: The Impact of Passive and Active Targeting in the Era of Modern Cancer Biology Adv. Drug Delivery Rev. 2014, 66, 2-25 10.1016/j.addr.2013.11.009
43. Lotfi-Jam, K.; Carey, M.; Jefford, M.; Schofield, P.; Charleson, C.; Aranda, S. Nonpharmacologic Strategies for Managing Common Chemotherapy Adverse Effects: A Systematic Review J. Clin. Oncol. 2008, 26, 5618-5629 10.1200/JCO.2007.15.9053
44. Liu, D.; Poon, C.; Lu, K.; He, C.; Lin, W. Self-Assembled Nanoscale Coordination Polymers with Trigger Release Properties for Effective Anticancer Therapy Nat. Commun. 2014, 5, 4182 10.1038/ncomms5182
45. Wang, D.; Stockard, C. R.; Harkins, L.; Lott, P.; Salih, C.; Yuan, K.; Buchsbaum, D.; Hashim, A.; Zayzafoon, M.; Hardy, R. W. et al. Immunohistochemistry in the Evaluation of Neovascularization in Tumor Xenografts Biotech. Histochem. 2008, 83, 179-189 10.1080/10520290802451085
46. Grant, D. S.; Williams, T. L.; Zahaczewsky, M.; Dicker, A. P. Comparison of Antiangiogenic Activities Using Paclitaxel (Taxol) and Docetaxel (Taxotere) Int. J. Cancer 2003, 104, 121-129 10.1002/ijc.10907
47. Haimovitz-Friedman, A.; Kan, C. C.; Ehleiter, D.; Persaud, R. S.; McLoughlin, M.; Fuks, Z.; Kolesnick, R. N. Ionizing Radiation Acts on Cellular Membranes to Generate Ceramide and Initiate Apoptosis J. Exp. Med. 1994, 180, 525-535 10.1084/jem.180.2.525
48. Kuo, L. J.; Yang, L. X. Gamma-H2ax-a Novel Biomarker for DNA Double-Strand Breaks In Vivo 2008, 22, 305-309
49. Werner, M. E.; Copp, J. A.; Karve, S.; Cummings, N. D.; Sukumar, R.; Li, C.; Napier, M. E.; Chen, R. C.; Cox, A. D.; Wang, A. Z. Folate-Targeted Polymeric Nanoparticle Formulation of Docetaxel Is an Effective Molecularly Targeted Radiosensitizer with Efficacy Dependent on the Timing of Radiotherapy ACS Nano 2011, 5, 8990-8998 10.1021/nn203165z
50. Lomax, M. E.; Folkes, L. K.; ONeill, P. Biological Consequences of Radiation-Induced DNA Damage: Relevance to Radiotherapy Clin. Oncol. (R. Coll. Radiol.) 2013, 25, 578-585 10.1016/j.clon.2013.06.007
51. Porter, A. G.; Jänicke, R. U. Emerging Roles of Caspase-3 in Apoptosis Cell Death Differ. 1999, 6, 99-104 10.1038/sj.cdd.4400476
52. Watters, D. Molecular Mechanisms of Ionizing Radiation-Induced Apoptosis Immunol. Cell Biol. 1999, 77, 263-271 10.1046/j.1440-1711.1999.00824.x